Skip to main content
HLB Life Science CO.,LTD. logo

HLB Life Science CO.,LTD. — Investor Relations & Filings

Ticker · 067630 ISIN · KR7067630004 LEI · 9884006PTFB20S9PS149 KO Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2021-02-25 Proxy Solicitation & In…
Country KR South Korea
Listing KO 067630

About HLB Life Science CO.,LTD.

https://www.hlb-lsmc.com/

HLB Life Science is a specialized pharmaceutical and biotechnology firm focused on the development of innovative anti-cancer medications and the manufacturing of medical devices. The company's research and development efforts center on targeted therapies and cell therapies for oncology. In parallel, it develops, manufactures, and distributes in vitro diagnostic (IVD) medical devices and quasi-drugs. The company's portfolio also includes the clinical development of anti-cancer drugs for animals, aiming to provide comprehensive solutions across human and animal health.

Recent filings

Filing Released Lang Actions
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for HLB Life Science. It outlines the date, location, agenda items (financial statement approval, director appointments, remuneration limits), and details regarding electronic voting. This type of document is sent to shareholders to provide information and request their participation/votes for the upcoming meeting, which aligns perfectly with the definition of a Proxy Solicitation & Information Statement.
2021-02-25 Korean
주주총회집중일개최사유신고
AGM Information Classification · 95% confidence The document is a formal notification filed by HLB Life Science regarding the scheduling of their Annual General Meeting (AGM) on a 'concentrated date' (a date when many companies hold their AGMs). It explains the necessity of this date due to audit report timelines. Since this is a regulatory notification regarding meeting logistics rather than the meeting materials themselves or the results of the meeting, it falls under the general regulatory filing category.
2021-02-25 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used by companies to solicit shareholder votes for an upcoming General Meeting. It contains details about the meeting date, agenda items (such as approval of financial statements), and instructions for electronic voting. This falls under the 'Proxy Solicitation & Information Statement' category.
2021-02-25 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for HLB Life Science. It contains the meeting agenda, details on voting procedures (including electronic voting), and management information such as director nominations and board activity reports. This document is a formal proxy statement/notice sent to shareholders to inform them of an upcoming meeting and solicit their votes, which fits the 'Proxy Solicitation & Information Statement' category.
2021-02-25 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (HLB Life Science) disclosing a significant change (over 30%) in revenue or profit structure. This type of disclosure is a standard regulatory requirement in the Korean market (DART system) for reporting material financial changes before the final audit is completed. It provides key financial highlights and reasons for the variance, fitting the definition of an Earnings Release (ER) as it serves as an initial announcement of financial performance metrics. FY 2020
2021-02-15 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the suspension of share registration (closing of the shareholder register) for the purpose of determining shareholders for an upcoming Annual General Meeting. It does not contain the full report or proxy materials, but rather serves as a formal regulatory notice of a corporate action. Given it does not fit into specific categories like dividend announcements or share buybacks, it falls under the general regulatory filing category.
2020-12-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.